Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Sunday, 3 June 2007

While You Were in the Cheap Seats

Posted on 21:00 by Unknown
Go Phils!

IN VIVO Blog took in the Phillies-Giants game at Citizens Bank Park in Philly on Sunday. Hopefully our readers had better weather (though the game was excellent!). A few tidbits from the weekend ...
  • It seems like Dr. John Buse's Congressional testimony on Wednesday will sure be interesting. The American Diabetes Association president-elect issued a statement on Friday (perhaps in an attempt to avoid mis-quotes), intended to be his only public communication until the testimony, that addresses the notion that GSK tried to silence his criticism of Avandia's risks in the past. NYT has the story, and Buse's statement.

  • ASCO ... ASCO, ASCO. Have you heard, there's an oncology conference in Chicago? Lots of news from Pfizer, GSK, BMS and the rest. Covered well over at the WSJ's Health Blog.

  • Wouldn't it be NICE? J&J has made the UK's National Institue for Clinical Excellence an offer it would be tough to refuse: the drugmaker will cover the cost of Velcade for patients who don't respond. The NIH would only pay when patients did well on the drug. Of course the details need to be ironed out. Full story at the FT. Hat tip Pharmalot.

  • Insider at Pharmagossip highlights Big Pharma's latest new media problem: Youtube. He also directs us to this recent Simpsons excerpt: "Nappien activates your brain's napping centers, and attacks your body's awakegens."

Email ThisBlogThis!Share to XShare to Facebook
Posted in Avandia, conference, Film and TV, NICE, While You Were ... | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • While You Were Settling
    Well, it was an interesting weekend: the writers' strike may have been settled, Obama swept (and won a Grammy), and there was an unusual...
  • EPO Relabeling: Its Not the Black Box, Its What FDA Says About the Black Box
    Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...
  • The Wacky World of Generics: Fosamax Edition
    Today, Merck bids a fond farewell to its Fosamax franchise, as the first generic versions enter the market. Three generic firms are enteri...
  • Higher Tax, Fewer Deals?
    The IN VIVO Blog has been somewhat mum on the carried interest debate. Frankly, this topic is being covered to death elsewhere (The link g...
  • CardioNet's Not So Big Surprise
    Riddle us this. When is news not news at all? When it’s involving CardioNet Inc.’s Friday filing for an IPO . See, this filing was essential...
  • While You Were Staying Put
    It's always sunny in ... London? Lets kick off the weekend wrap-up by highlighting a trio of stories from The Times about incoming Glax...
  • While You Were Almost Upsetting
    We've been told by certain football (soccer) fans that there are not enough allusions to the beautiful game in our weekend roundups. So ...
  • FDA’s Search for a Drug Chief Not Going Well: An Internal Candidate Emerges
    We know all of you have been passing the time following the Presidential Primaries when the race you’re really interested in is who the next...
  • While You Were Redesigning Your Blog
    Does our blog look big in this? You may have noticed a few changes round these parts, and we hope you like them. No, not that the pace of o...
  • The Downsizing Opportunity: Pipeline on the Cheap?
    The IN VIVO Blog was in Michigan last week, attending a profiting-from-downsizing symposium. Would Pfizer—we wondered at the Michigan Growth...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ▼  June (39)
      • Could've Seen That One Coming
      • Private Equity: Muscling in on Big Pharma at Biote...
      • Live from Paris: Roger's dealmaking overview
      • In Our Face
      • Welcome to Paris: take my drug ... Please
      • Roche to Ventana: We want you so bad
      • Good Things Come
      • Roche makes Ventana an offer it may or may not be ...
      • Big Week For the Bushes
      • Venture Debt in Europe: Opportunity Missed?
      • While You Were at ADA
      • Brailer's New Quest
      • The Wrong Man for This Job
      • Overheard at the London Stock Exchange Mediscience...
      • Preserving the Right to Advertise—No Matter How Du...
      • Sometimes the Bear Gets You: Coley Pharmaceuticals...
      • Why No More Roche-Genentechs?
      • Size Matters for Specialist Drugs, Too
      • The Other Surge
      • Should Some of these Butterflies Get Eaten?
      • While You Were Celebrating Father's Day ...
      • What Drug Makers Can Learn from Vaccines
      • Rimonabant’s Risky Business
      • Is FDA Killing Research?
      • Record VC dough for device makers
      • Israel’s Public Venture Market
      • CVS/Caremark Loses a Big One
      • Fat Chance for Rimonabant
      • Launching Alli
      • While You Were Watching the Finale
      • It must be two-for-one week on private biotechs
      • The Wisdom of Buybacks
      • PhRMA's DTC Verdict: it ain't broke, we're not gon...
      • R&D: Worth It Only When You Don’t Pay for It
      • Amgen buys Ilypsa for $420mm cash
      • Hi, I’m from Medtronic. My name is …
      • No Cure, No Pay
      • While You Were in the Cheap Seats
      • Jazz IPO Fails to Generate Buzz
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile